Quick answer: Saxenda is liraglutide 3.0 mg, a daily GLP-1 injection and the first of this class approved for weight management. In the SCALE trial it produced roughly 8% mean body-weight reduction at 56 weeks — meaningful, but less than semaglutide's 14.9% or tirzepatide's up to 20.9%. It is a daily injection rather than weekly, which makes it a harder regimen for most people to sustain.
The original weight-loss GLP-1
Liraglutide arrived years before semaglutide and tirzepatide and established that a GLP-1 receptor agonist could produce clinically useful weight loss. The SCALE trial demonstrated this at the 3.0 mg dose. Everything that followed built on that result.
Its problem in 2026 is simply that the newer molecules are better on both axes patients care about: more weight lost, and one injection a week instead of seven.
How it compares
- Liraglutide 3.0 mg (SCALE): around 8% mean body-weight reduction at 56 weeks, injected daily.
- Semaglutide 2.4 mg (STEP 1): 14.9% at 68 weeks, injected weekly.
- Tirzepatide (SURMOUNT-1): up to 20.9% at 72 weeks, injected weekly.
Those trials differ in design and population, so this is a rough ordering rather than a precise ranking. But the direction is consistent and it is why liraglutide is now a second-line choice for most people.
Does daily dosing matter?
More than the pharmacology suggests. Seven injections a week is roughly thirty a month and over three hundred a year. Adherence erodes, and a medicine you skip does not work. For most patients the weekly options are easier to sustain over the twelve to eighteen months that meaningful metabolic change takes.
There is one narrow advantage: because liraglutide clears from the body faster, side effects also resolve faster if you need to stop. That can occasionally matter for someone particularly worried about tolerability.
When liraglutide still makes sense
It remains a legitimate option when supply of the newer medicines is constrained, when cost works out favourably for you, when you have tolerated it well before, or when your clinician has a specific reason to prefer a shorter-acting agent.
What has not changed
The fundamentals are identical across the class. Side effects are mostly gastrointestinal and concentrated during dose escalation. Gallbladder risk is increased. Muscle is lost alongside fat unless you defend it with adequate protein and resistance training. And weight tends to return after stopping unless a maintenance plan exists from the beginning.
If you are starting fresh in 2026, the honest conversation with your doctor is usually about semaglutide or tirzepatide first, with liraglutide as a considered alternative rather than a default.
